



lukman hakim <lukman-h@fk.unair.ac.id>

Submission Confirmation

Current Clinical Microbiology Reports <em@editorialmanager.com>
Reply-To: Current Clinical Microbiology Reports <annielyn.ramos@springer.com>
To: Lukman Hakim <lukman-h@fk.unair.ac.id>

Sat, Dec 18, 2021 at 9:52 AM

Dear Dr. Hakim,

Thank you for submitting your manuscript,
"Prostate Cancer Microbiome: A Narrative Review of What We Know So Far", to Current Clinical Microbiology Reports

The submission id is: CCMR-D-21-00038
Please refer to this number in any future correspondence.

During the review process, you can keep track of the status of your manuscript by accessing the journal's web site.

Your username is: lukmanhakim
If you forgot your password, you can click the 'Send Login Details' link on the EM Login page at
<https://www.editorialmanager.com/ccmr/>.

With kind regards,

Journals Editorial Office CCMR
Springer

This letter contains confidential information, is for your own use, and should not be forwarded to third parties.

Recipients of this email are registered users within the Editorial Manager database for this journal. We will keep your information on file to use in the process of submitting, evaluating and publishing a manuscript. For more information on how we use your personal details please see our privacy policy at <https://www.springernature.com/production-privacy-policy>. If you no longer wish to receive messages from this journal or you have questions regarding database management, please contact the Publication Office at the link below.
%CUSTOM_PUBLICATION_OFFICE_EMAIL_ADDRESS%

In compliance with data protection regulations, you may request that we remove your personal registration details at any time. (Use the following URL: <https://www.editorialmanager.com/ccmr/login.asp?a=r>). Please contact the publication office if you have any questions.



lukman hakim <lukman-h@fk.unair.ac.id>

Your submission to Current Clinical Microbiology Reports

7 messages

Jeffrey Gunning <jeffrey.gunning@springer.com>
To: "lukman-h@fk.unair.ac.id" <lukman-h@fk.unair.ac.id>

Wed, Dec 22, 2021 at 10:48 PM

Hello Dr. Hakim,

My name is Jeff Gunning and I am the editor of Current Clinical Microbiology Reports. I've noticed that you have recently submitted an article to the journal in Editorial Manager.

When you have the chance, please send me the article via email for an initial check in. If everything is formatted correctly, I will be glad to send it to the Editor-in-Chief to review or assign a reviewer. In the meantime, I will remove your initial submission from the system.

Thank you!

Jeff

Jeff Gunning

Senior Editor

Reviews Journals

Springer

1650 Arch Street | Suite 2050 | Philadelphia, PA 19103

T +1-267-321-5511

F +1-215-574-2270

jeffrey.gunning@springer.com

www.Springer.com

Springer is a leading global science, technology, medicine, humanities and social sciences portfolio of innovative information, products and services that provides researchers in academia, scientific institutions and corporate R&D departments with quality content. Springer is part of Springer Nature, one of the world's leading global research, educational and professional publishers.



Follow Current Reports and Current Treatment Options

@SpringerCurRpts on [Twitter](#).

lukman hakim <lukman-h@fk.unair.ac.id>
To: Jeffrey Gunning <jeffrey.gunning@springer.com>

Thu, Dec 23, 2021 at 9:18 AM

Dear Dr. Jeffrey Gunning,

Thank you for notifying us regarding our submission. We hereby attach the article below for an initial check-in. We hope that it will be considered for review. Thank you.

Warmest regards,

Lukman Hakim
[Quoted text hidden]

4 attachments




Figure 1.png
401K

Declarations.docx
13K

Cover Letter.docx
14K

Manuscript.docx
65K

Jeffrey Gunning <jeffrey.gunning@springer.com>
To: lukman hakim <lukman-h@fk.unair.ac.id>

Thu, Dec 23, 2021 at 8:11 PM

Dr. Hakim,

Thank you very much for submitting your manuscript. I've looked it over and before we can move forward with it, I will need the following:

1. You and your coauthor will need to complete the attached disclosure form.
2. Please include the following headings within the Abstract: Purpose of Review, Recent Findings, and Summary (see attached sample and instructions).
3. Please also include an Introduction section (see sample and instructions).
4. Is Figure 1 original? If not, have you obtained permission to use it?

5. Lastly, please highlight (single or double bullet) a few key references published within the last 3 years and provide a brief explanation of their importance (see sample and instructions).

Thank you!

Jeff

From: lukman hakim <lukman-h@fk.unair.ac.id>
Sent: Wednesday, December 22, 2021 9:18 PM
To: Jeffrey Gunning <jeffrey.gunning@springer.com>
Subject: Re: Your submission to Current Clinical Microbiology Reports

[External - Use Caution]

[Quoted text hidden]

3 attachments

 **Author Instructions-CCMR.pdf**
1256K

 **CCMR Sample Article.pdf**
2711K

 **NEW ICJME coi_disclosure.pdf**
1210K

lukman hakim <lukman-h@fk.unair.ac.id>
To: Jeffrey Gunning <jeffrey.gunning@springer.com>

Sun, Jan 2, 2022 at 8:14 PM

Dear Dr. Jeffrey Gunning,

Thank you for reviewing our submission. We have performed the following:

1. We have completed the disclosure form and attached the files below.
2. We have revised the abstract accordingly.
3. We have added an introduction section.
4. We have added an original figure to the manuscript.
5. We have highlighted several important references with single and double bullets. We have also added a brief explanation below each reference on the list. A separate file is attached below in case the reference manager automatically removes the bullet point and brief explanations.

Thank you, we hope that the article will be considered for publication.

Warmest regards,

Lukman Hakim

[Quoted text hidden]

5 attachments





Figure 1.jpg
453K

 **Manuscript.docx**
70K

 **Important References.docx**
17K

 **NEW ICJME coi_disclosure Lukman Hakim.pdf**
968K

 **NEW ICJME coi_disclosure_Yudhistira.pdf**
1225K

Jeffrey Gunning <jeffrey.gunning@springer.com>
To: lukman hakim <lukman-h@fk.unair.ac.id>

Sat, Jan 8, 2022 at 2:05 AM

Thank you very much Dr. Hakim. I will now send your manuscript to our Editor-in-Chief to review or assign a Section Editor to review it.

I will be in touch!

Have a great weekend!

[Quoted text hidden]

lukman hakim <lukman-h@fk.unair.ac.id>
To: Jeffrey Gunning <jeffrey.gunning@springer.com>

Sat, Jan 8, 2022 at 8:07 PM

Dear Dr. Jeffrey Gunning,

Thank you so much for considering our manuscript for review.

Warmest regards,

Lukman Hakim
[Quoted text hidden]

lukman hakim <lukman-h@fk.unair.ac.id>
To: Yudhistira Kloping <distrayyss@gmail.com>

Mon, Jan 10, 2022 at 12:41 PM

----- Forwarded message -----

From: **lukman hakim** <lukman-h@fk.unair.ac.id>
Date: Thu, Dec 23, 2021, 09:18
Subject: Re: Your submission to Current Clinical Microbiology Reports
To: Jeffrey Gunning <jeffrey.gunning@springer.com>

[Quoted text hidden]

4 attachments





Figure 1.png
401K

 **Declarations.docx**
13K

 **Cover Letter.docx**
14K

 **Manuscript.docx**
65K



lukman hakim <lukman-h@fk.unair.ac.id>

Current Clinical Microbiology Reports: Article Update

12 messages

Benjamin Riley <benjamin.riley@springernature.com>
To: "lukman-h@fk.unair.ac.id" <lukman-h@fk.unair.ac.id>

Thu, Feb 24, 2022 at 11:01 PM

Dear Dr. Hakim,

I hope you are keeping well. My name is Ben Riley and I am the Publishing Editor for *Current Clinical Microbiology Reports*.

I am reaching out with an update on your submitted manuscript: your article has been reviewed, and requires additional revisions. Please see below for the full review:

“This study by Klopın and Hakim reviews the role of the microbiota in causing prostate cancer. The manuscript does a good job of reviewing the current state of knowledge on the topic but fails to be insightful for future studies. I was particularly distressed by the lack of any decent proof-reading of the manuscript. Several major findings have been left unattributed without a proper reference. Simple acts of italicizing scientific names have been ignored, line numbers have not been assigned. I understand many authors do not have a command over the English language, but I cannot understand why a simple spell-check function cannot be employed before submission. More importantly, the authors fail to provide any further insights into mechanisms that may implicate microbial roles in tumorigenesis and further progression into cancerous state. A review is hardly complete without the synthesis of the current knowledge into actionable proposals. This is particularly important for such a wide-spread disease like prostate cancer which the authors fail to provide. Another major drawback is the complete absence of any mention of the different genes and genetic pathways that have been implicated to produce prostate cancer. The same pathways are also used by many common microbes to elicit specific phenotypes. Therefore, I cannot recommend acceptance of this manuscript in its current state.

Minor comments:

1. In the abstract: change increases to raises.
2. Please add a reference for: organism that resides in a particular environment.
3. What is 'bio-information'?
4. Please add a reference for: Approximately 20% of a malignancy's etiopathogenesis is related to the role of a microorganism...
5. Please add a reference for: Theoretically, natural microbiotic changes can increase the risk of prostate cancer development.... And many other such statements!
6. Several scientific names have not been italicized.”

Please complete the requested revisions and submit your revised manuscript to Editorial Manager for further review via the following link: <https://www.editorialmanager.com/ccmr/default1.aspx>.

Please feel free to reach out with any questions or concerns. I look forward to hearing from you.

All best,

Ben Riley

Associate Editor

Current Reports

(he/him/his)

Springer, part of **SpringerNature**

1 New York Plaza

Suite 4600

New York, NY 10004-1562

T +1-212-726-9259

Benjamin.Riley@springernature.com

www.springer.com

Springer is a leading global science, technology, medicine, humanities and social sciences portfolio of innovative information, products and services, that provide researchers in academia, scientific institutions and corporate R&D departments with quality content. Springer is part of Springer Nature, one of the world's leading global research, educational and professional publishers.



Follow Current Reports and Current Treatment Options

@SpringerCurRpts on [Twitter](#).

lukman hakim <lukman-h@fk.unair.ac.id>
To: Yudhistira Pradnyan Kloping <yudhistira.pradnyan.kloping-2020@fk.unair.ac.id>

Sun, Feb 27, 2022 at 3:21 PM

[Quoted text hidden]

Benjamin Riley <benjamin.riley@springernature.com>
To: "lukman-h@fk.unair.ac.id" <lukman-h@fk.unair.ac.id>
Cc: Rhitoban Ray Ray Choudhury <rhitoban@iisermohali.ac.in>

Thu, Mar 3, 2022 at 2:29 AM

Dear Dr. Hakim,

I hope you are keeping well. I am following up regarding the requested revisions for your manuscript. How are they coming along? Any update you could provide would be greatly appreciated.

Please respond with your answer by next **Wednesday, March 9th, 2022.**

I look forward to hearing from you soon.

All best,

Ben Riley

Associate Editor

Current Reports

(he/him/his)

Springer, part of **SpringerNature**

1 New York Plaza

Suite 4600

New York, NY 10004-1562

T +1-212-726-9259

Benjamin.Riley@springernature.com

www.springer.com

Springer is a leading global science, technology, medicine, humanities and social sciences portfolio of innovative information, products and services, that provide researchers in academia, scientific institutions and corporate R&D departments with quality content. Springer is part of Springer Nature, one of the world's leading global research, educational and professional publishers.



Follow Current Reports and Current Treatment Options

@SpringerCurRpts on [Twitter](#).

From: Benjamin Riley
Sent: Thursday, February 24, 2022 11:02 AM
To: lukman-h@fk.unair.ac.id
Subject: Current Clinical Microbiology Reports: Article Update

Dear Dr. Hakim,

[Quoted text hidden]

lukman hakim <lukman-h@fk.unair.ac.id>
To: Benjamin Riley <benjamin.riley@springernature.com>

Fri, Mar 4, 2022 at 3:57 PM

Dear Dr. Benjamin Riley,

Thank you for contacting us regarding our submission. We are currently revising the manuscript. We will submit the revised version via the editorial manager website soon.

Warmest regards,

Lukman Hakim
[Quoted text hidden]

Benjamin Riley <benjamin.riley@springernature.com>
To: lukman hakim <lukman-h@fk.unair.ac.id>

Fri, Mar 4, 2022 at 9:56 PM

Dear Dr. Hakim,

Thank you for this update. We look forward to receiving your revised manuscript soon.

All best,

Ben Riley

Associate Editor

Current Reports

(he/him/his)

Springer, part of **SpringerNature**

1 New York Plaza

Suite 4600

New York, NY 10004-1562

T +1-212-726-9259

Benjamin.Riley@springernature.comwww.springer.com

Springer is a leading global science, technology, medicine, humanities and social sciences portfolio of innovative information, products and services, that provide researchers in academia, scientific institutions and corporate R&D departments with quality content. Springer is part of Springer Nature, one of the world's leading global research, educational and professional publishers.

**Follow Current Reports and Current Treatment Options****@SpringerCurRpts on [Twitter](#).**

From: lukman hakim <lukman-h@fk.unair.ac.id>**Sent:** Friday, March 4, 2022 3:58 AM**To:** Benjamin Riley <benjamin.riley@springernature.com>**Subject:** Re: Current Clinical Microbiology Reports: Article Update

[External - Use Caution]

[Quoted text hidden]

lukman hakim <lukman-h@fk.unair.ac.id>
To: Benjamin Riley <benjamin.riley@springernature.com>

Thu, Mar 10, 2022 at 1:39 AM

Dear Dr. Benjamin Riley,

We have submitted the revised manuscript via the editorial manager. The assigned number of the manuscript is "CCMR-D-22-00012". Thank you for reviewing our submission.

Warmest regards,

Lukman Hakim
[Quoted text hidden]

Benjamin Riley <benjamin.riley@springernature.com>
To: lukman hakim <lukman-h@fk.unair.ac.id>

Thu, Mar 10, 2022 at 2:08 AM

Dear Dr. Hakim,

Thank you for this update and for submitting your revised manuscript in Editorial Manager. Confirming that we have received your manuscript. You will receive notification from Editorial Manager as soon as a decision has been rendered.

In the meantime, please feel free to let me know if you have any questions.

Best,

[Quoted text hidden]

Benjamin Riley <benjamin.riley@springernature.com>
To: lukman hakim <lukman-h@fk.unair.ac.id>
Cc: Yohei Yamauchi <yohei.yamauchi@bristol.ac.uk>

Mon, Mar 14, 2022 at 9:33 PM

Dear Dr. Hakim,

I hope you are keeping well. I am reaching out with an update on the status of your article: your article has been reviewed (see below for comments and requested revisions). Please re-submit your revised article to Editorial Manager by **3/18/2022** in order for your article to move forward in the review process.

Please let me know if you have any questions. We look forward to receiving your revised manuscript soon.

Best,

Ben Riley

Associate Editor

Current Reports

(he/him/his)

Springer, part of **SpringerNature**

1 New York Plaza

Suite 4600

New York, NY 10004-1562

T +1-212-726-9259

Benjamin.Riley@springernature.comwww.springer.com

Springer is a leading global science, technology, medicine, humanities and social sciences portfolio of innovative information, products and services, that provide researchers in academia, scientific institutions and corporate R&D departments with quality content. Springer is part of Springer Nature, one of the world's leading global research, educational and professional publishers.

**Follow Current Reports and Current Treatment Options****@SpringerCurRpts on [Twitter](#).**

COMMENTS FOR THE AUTHOR:

The authors review microbiome and risk of prostate cancer development. Particularly the review covers prostate and urinary tract microbiome, clinical applications etc. in prostate cancer patients.

Comments:

If there is any literature on changes in the microbiome of patients treated for prostate cancer such as hormonal treatment, please include.

For example, <https://link.springer.com/article/10.1007/s40618-020-01424-0> points to gut microbiome changes, and possibly other studies.

Minor points:

Page 6 line 14: Banerjee et al.

Line 17: One of the major findings was the presence of...

Line 34: could not be ruled out.

[Quoted text hidden]

Benjamin Riley <benjamin.riley@springernature.com>
To: lukman hakim <lukman-h@fk.unair.ac.id>
Cc: Yohei Yamauchi <yohei.yamauchi@bristol.ac.uk>

Tue, Mar 15, 2022 at 10:02 PM

Dear Dr. Hakim,

Thank you for submitting your revised article. I am reaching out because your revised submission appears as “incomplete” in Editorial Manager. Please re-submit your complete revised manuscript via Editorial Manager by **3/18/2022**.

In the meantime, feel free to let me know if you have any questions. We look forward to receiving your manuscript.

[Quoted text hidden]

I hope you are keeping well. I am reaching out with an update on the status of your article: your article has been reviewed (see below for comments and requested revisions). Please re-submit your revised article to Editorial Manager by **3/18/2022** in order for your article to move forward in the review process.

Please let me know if you have any questions. We look forward to receiving your revised manuscript soon.

Best,

Ben Riley

Associate Editor

Current Reports

(he/him/his)

Springer, part of **SpringerNature**

1 New York Plaza

Suite 4600

New York, NY 10004-1562

T +1-212-726-9259

Benjamin.Riley@springernature.com

www.springer.com

Springer is a leading global science, technology, medicine, humanities and social sciences portfolio of innovative information, products and services, that provide researchers in academia, scientific institutions and corporate R&D departments with quality content. Springer is part of Springer Nature, one of the world's leading global research, educational and professional publishers.



Follow Current Reports and Current Treatment Options

@SpringerCurRpts on [Twitter](#).

COMMENTS FOR THE AUTHOR:

The authors review microbiome and risk of prostate cancer development. Particularly the review covers prostate and urinary tract microbiome, clinical applications etc. in prostate cancer patients.

Comments:

If there is any literature on changes in the microbiome of patients treated for prostate cancer such as hormonal treatment, please include.

For example, <https://link.springer.com/article/10.1007/s40618-020-01424-0> points to gut microbiome changes, and possibly other studies.

Minor points:

Page 6 line 14: Banerjee et al.

Line 17: One of the major findings was the presence of...

Line 34: could not be ruled out.

From: Benjamin Riley

Sent: Wednesday, March 9, 2022 2:08 PM

[Quoted text hidden]

[Quoted text hidden]

lukman hakim <lukman-h@fk.unair.ac.id>
To: Benjamin Riley <benjamin.riley@springernature.com>

Sat, Mar 19, 2022 at 3:54 PM

Dear Dr. Benjamin Riley,

We have submitted the revised manuscript via the editorial manager. Thank you for the reminder. We look forward to hearing from you soon.

Warmest regards,

Lukman Hakim
[Quoted text hidden]

7 attachments

image001.jpg
1K



image001.jpg
1K



image001.jpg
1K



image001.jpg
1K



image001.jpg
1K



image001.jpg
1K



image001.jpg
1K

Benjamin Riley <benjamin.riley@springernature.com>
To: lukman hakim <lukman-h@fk.unair.ac.id>

Mon, Mar 21, 2022 at 8:21 PM

Dear Dr. Hakim,

Thank you for this update and for promptly submitting your revised manuscript via Editorial Manager. Confirming that we have received your manuscript and it has been assigned for further review. You will receive a notification from Editorial Manager informing you of the reviewers' decision shortly.

In the meantime, please let me know if you have any questions.

[Quoted text hidden]

Benjamin Riley <benjamin.riley@springernature.com>
To: lukman hakim <lukman-h@fk.unair.ac.id>

Sat, Mar 26, 2022 at 1:32 AM

Dear Dr. Hakim,

I write with good news: your article has been accepted and approved for publication. As the corresponding author, you will receive an email from Production, so please be on the lookout for an email from Springer in the near future.

In the email from Production you will be sent a link with a secure code where you can fill out the online forms for your article to go through the MyPublication process (see <https://www.springer.com/de/authors-editors/journal-author/journal-author-helpdesk/mypublication/1264> for details about this process). This is where you will decide how to have your article published, by either transferring the copyright over to Springer (no fees), or you can choose open access (which has fees and enables your article to be freely accessible).*

*For OA funding questions, Authors should first check with their institutions. Authors can check whether their institution has an agreement with SN on the website: <https://www.springernature.com/gp/open-research/institutional-agreements>. Or the author can contact OAFundingpolicy@springernature.com to find out what funding may be available to them.

Once the MyPublication process is completed, you will be emailed a link to the proof of your article to review. After you have reviewed and approved the proof of your article, the article will be published online.

****Also, Springer has a new option where you can track your article. See more details below.**

Article tracking will guide you through the 7 stages from the moment your article has been accepted until it is published in print. Every step is described and will let you know whether action on your part is required. Please log in to your personal [springer.com](https://www.springer.com) account to start tracking your new articles!

It has been a pleasure to work with you on this article, and we appreciate your contribution to this journal. Please feel free to reach out if you have any questions.

Sincerely,

[Quoted text hidden]



lukman hakim <lukman-h@fk.unair.ac.id>

Decision on your manuscript #CCMR-D-22-00012R1 - [EMID:e18f84033195a275]

Current Clinical Microbiology Reports <em@editorialmanager.com>
Reply-To: Current Clinical Microbiology Reports <annielyn.ramos@springer.com>
To: Lukman Hakim <lukman-h@fk.unair.ac.id>

Thu, Mar 24, 2022 at 10:41 PM

Dear Hakim,

We are pleased to inform you that your manuscript, "Prostate Cancer Microbiome: A Narrative Review of What We Know So Far", has been accepted for publication in Current Clinical Microbiology Reports.

You will receive an e-mail in due course regarding the production process.

Please remember to quote the manuscript number, CCMR-D-22-00012R1, whenever inquiring about your manuscript.

With kind regards,
Yohei Yamauchi
Editor in Chief
Current Clinical Microbiology Reports

In compliance with data protection regulations, you may request that we remove your personal registration details at any time. (Use the following URL: <https://www.editorialmanager.com/ccmr/login.asp?a=r>). Please contact the publication office if you have any questions.